Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Cost of illness of hyponatremia in the United States.

Boscoe A, Paramore C, Verbalis JG.

Cost Eff Resour Alloc. 2006 May 31;4:10.

2.

Economic costs of diabetes in the U.S. In 2007.

American Diabetes Association..

Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Review. Erratum in: Diabetes Care. 2008 Jun;31(6):1271.

PMID:
18308683
3.

Evidence Brief: Effectiveness of Intensive Primary Care Programs.

Peterson K, Helfand M, Humphrey L, Christensen V, Carson S.

VA Evidence-based Synthesis Program Evidence Briefs [Internet]. Washington (DC): Department of Veterans Affairs (US); 2011-.
2013 Feb.

4.

Economic burden of urgency urinary incontinence in the United States: a systematic review.

Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I.

J Manag Care Pharm. 2014 Feb;20(2):130-40. Review.

5.

Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States.

Smith AF, Waycaster C.

BMC Ophthalmol. 2009 Nov 25;9:13. doi: 10.1186/1471-2415-9-13. Review.

6.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
7.

The estimated annual cost of uterine leiomyomata in the United States.

Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH.

Am J Obstet Gynecol. 2012 Mar;206(3):211.e1-9. doi: 10.1016/j.ajog.2011.12.002. Epub 2011 Dec 11. Review.

8.

A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.

Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT.

J Manag Care Pharm. 2013 Nov-Dec;19(9):755-64. Review.

9.

Current estimates of the economic cost of obesity in the United States.

Wolf AM, Colditz GA.

Obes Res. 1998 Mar;6(2):97-106. Review.

12.

Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature.

Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J.

COPD. 2006 Dec;3(4):211-8. Review.

PMID:
17361502
13.

[Etiology, diagnostics and therapy of hyponatremias].

Laczi F.

Orv Hetil. 2008 Jul 20;149(29):1347-54. doi: 10.1556/OH.2008.28409. Review. Hungarian.

PMID:
18617466
14.

Where vaptans do and do not fit in the treatment of hyponatremia.

Jovanovich AJ, Berl T.

Kidney Int. 2013 Apr;83(4):563-7. doi: 10.1038/ki.2012.402. Epub 2012 Dec 19. Review.

15.

Consequences of inadequate management of hyponatremia.

Adrogué HJ.

Am J Nephrol. 2005 May-Jun;25(3):240-9. Epub 2005 May 25. Review.

16.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
17.

[Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study].

Marcellusi A, Viti R, Incorvaia C, Mennini FS.

Recenti Prog Med. 2015 Oct;106(10):517-27. doi: 10.1701/2032.22086. Review. Italian.

PMID:
26442978
18.

Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span.

Azziz R, Marin C, Hoq L, Badamgarav E, Song P.

J Clin Endocrinol Metab. 2005 Aug;90(8):4650-8. Epub 2005 Jun 8. Review.

PMID:
15944216
19.

Costs of bipolar disorder.

Kleinman L, Lowin A, Flood E, Gandhi G, Edgell E, Revicki D.

Pharmacoeconomics. 2003;21(9):601-22. Review.

PMID:
12807364

Supplemental Content

Support Center